Homepage Top Section1

Based on the result of the primary endpoint, Lilly has dropped its plan to pursue regulatory submission for solanezumab in people having dominantly inherited Alzheimer’s disease (DIAD) or

Under an exclusive worldwide licence, Aimmune will develop and commercialise the XmAb 7195, an investigational humanised monoclonal antibody. Xencor president and CEO Dr Bassil Dahiyat said: “Aimmune’s focus,

The supplemental New Drug Application (sNDA), which has been filed by the company and accepted by the regulator, is seeking approval for using Recarbrio for treating adult patients

Palforzia, which was formerly known as AR101, has been indicated in the US for the mitigation of anaphylaxis and other allergic reactions following accidental exposure to peanut. The

The company, through its new drug application (NDA), has been seeking FDA approval for selpercatinib for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET

In this connection, Accenture will use Google Cloud as the cloud technology provider for its INTIENT life sciences industry platform. The new, multi-year partnership will see Google’s cloud

The deals are being carried out to help in facilitating the closing of the previously announced $63bn acquisition of Allergan by AbbVie. Brazikumab is an investigational IL-23 inhibitor,

DS-8201 is trastuzumab deruxtecan in Japan and other regions of world barring the US where it is fam-trastuzumab deruxtecan-nxki. The mid-stage trial for the ADC was held in

North Carolina Governor Roy Cooper has also announced that Eli Lilly’s move will also help to create over 460 new jobs in the Durham region. The new job